ZS Pharma Announces Positive Top-Line Results from HARMONIZE (ZS004), a Second Phase 3 Clinical Trial of ZS-9 in Patients with Hyperkalemia

ZS-9 meets primary endpoint at all three doses tested

Coppell, Texas – September 23, 2014 – ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced positive top-line results from HARMONIZE (ZS004), its second Phase 3 clinical trial of ZS-9 (sodium zirconium cyclosilicate), a novel investigational treatment for hyperkalemia.

Read More

ZS Pharma Presents New Data from ZS003 a Two Week Phase 3 Trial Demonstrating that ZS-9 Prevented Recurrence of Hyperkalemia in Heart Failure Patients on RAASi

Data Featured as Oral Presentation During a Late-Breaking Clinical Trial Session at the Heart Failure Society of America (HFSA) 18th Annual Scientific Meeting

 Coppell, Texas – September 15, 2014 - ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced results of a secondary analysis of ZS003, a two week pivotal Phase 3 trial of ZS-9 (sodium zirconium cyclosilicate),

Read More

RiverVest invests in Tryton’s $20 million funding round

By:  Brian Feldt, St. Louis Business Journal

September 8, 2014

Tryton Medical, a company developing stents to treat coronary bifurcation lesions, has raised $20 million in equity from a group of investors that includes St. Louis-based RiverVest Venture Partners and the 3×5 Special Opportunity Fund.

Both RiverVest and the 3X5 fund, which is co-managed by RiverVest, have participated in funding rounds for Tryton before, most recently in a $24 million equity financing round for the Durham, North Carolina-based company in early 2013.   Read more

Read More

RiverVest Venture Partners’ Otonomy Completes $100 Million Initial Public Offering

ST. LOUIS and SAN DIEGO (Aug. 13, 2014) – Otonomy, Inc., a RiverVest Fund II portfolio company that develops drug therapies for the inner and middle ear, announced today its $100 million initial public offering.

Read More